This filing is administrative; monitor for the effective date of the registration statement and any subsequent ELOC draws, which would signal immediate dilution. The company's $5M market cap makes even modest draws highly dilutive.
Executive Summary
Onconetix filed Amendment No. 1 to its S-1 registration statement, purely to add Exhibit 5.1 (legal opinion from Ellenoff Grossman & Schole LLP). The underlying registration covers the resale of up to 25 million shares by Keystone Capital Partners under an existing ELOC Purchase Agreement. This amendment is procedural and does not change the terms of the offering.
Key Facts
- Amendment No. 1 to S-1 adds only Exhibit 5.1 (legal opinion), leaving all other terms unchanged.
- Registration covers up to 25,000,000 shares of common stock for resale by Keystone Capital Partners.
- The shares are issuable under an ELOC Purchase Agreement dated October 2, 2024, which could provide up to $25 million in gross proceeds.
- Company is a pharmaceutical preparation firm with a $5M market cap and no analyst bullish sentiment.
- Historical model performance on ONCO (0% win rate at T+20) suggests caution on scoring.
Financial Impact
No financial impact from this amendment; the underlying ELOC has potential $25M dilution if fully drawn.
Risk Factors
- Substantial dilution potential from the ELOC facility (up to 25M shares relative to $5M market cap).
- Company has negative historical stock performance and no analyst support.
- Procedural filings often precede accelerated selling by the ELOC counterparty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001213900-26-053255 |
| Document: ea028969801ex5-1.htm | 0001213900-26-053255 |
| Document: 0001213900-26-053255-index-headers.html | 0001213900-26-053255 |
| Document: 0001213900-26-053255-index.html | 0001213900-26-053255 |
| Document: 0001213900-26-053255.txt | 0001213900-26-053255 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | DEFA14A / 8-K | $0.6374 $0.6549 | ▲ +2.75% | ▲ +2.64% | $0.7440 (+16.72%) |
Sep 14, 2026 18d ago | 8-K | $0.6374 $0.6549 | ▼ −2.75% | ▼ −2.64% | $0.7440 (−16.72%) |
Sep 14, 2026 18d ago | 425 | $0.6374 $0.6549 | ▼ −2.75% | ▼ −2.64% | $0.7440 (−16.72%) |
Sep 4, 2026 28d ago | EFFECT | $1.02 $0.6374 | ▲ +37.51% | ▲ +36.30% | $0.7440 (+27.06%) |
Sep 3, 2026 29d ago | 425 | $0.7390 $0.7564 | ▲ +2.35% | ▲ +3.50% | $0.7440 (+0.68%) |
Aug 31, 2026 4w ago | S-1/A | $0.6528 $0.8132 | ▼ −24.57% | ▼ −24.49% | $0.7440 (−13.97%) |
Aug 12, 2026 7w ago | S-1 | $0.8920 $0.7110 | ▲ +20.29% | ▲ +19.85% | $0.7440 (+16.59%) |
Jul 29, 2026 9w ago | 8-K | $0.7864 $0.9037 | ▼ −14.92% | ▼ −11.29% | $0.7440 (+5.39%) |
Jul 7, 2026 12w ago | 425 | $1.07 $0.8487 | ▼ −20.68% | ▼ −21.23% | $0.7440 (−30.47%) |
Jun 17, 2026 15w ago | EFFECT | $0.9949 $1.00 | ▼ −0.51% | ▼ −1.55% | $0.7440 (+25.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access